Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Missense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functions
Yenthe Monnens, Anastasia Theodoropoulou, Karen Rosier, Kritika Bhalla, Alexia Mahy, Roeland Vanhoutte, Sandra Meulemans, Edoardo Cavani, Aleksandar Antanasijevic, Irma Lemmens, Jennifer A. Lee, Catherine J. Spellicy, Richard J. Schroer, Ricardo A. Maselli, Chamindra G. Laverty, Patrizia Agostinis, David J. Pagliarini, Steven Verhelst, Maria J. Marcaida, Anne Rochtus, Matteo Dal Peraro, John W.M. Creemers
Yenthe Monnens, Anastasia Theodoropoulou, Karen Rosier, Kritika Bhalla, Alexia Mahy, Roeland Vanhoutte, Sandra Meulemans, Edoardo Cavani, Aleksandar Antanasijevic, Irma Lemmens, Jennifer A. Lee, Catherine J. Spellicy, Richard J. Schroer, Ricardo A. Maselli, Chamindra G. Laverty, Patrizia Agostinis, David J. Pagliarini, Steven Verhelst, Maria J. Marcaida, Anne Rochtus, Matteo Dal Peraro, John W.M. Creemers
View: Text | PDF
Research Article Endocrinology Genetics

Missense variants in CMS22 patients reveal that PREPL has both enzymatic and nonenzymatic functions

  • Text
  • PDF
Abstract

Congenital myasthenic syndrome-22 (CMS22, OMIM 616224) is a rare genetic disorder caused by deleterious genetic variation in the prolyl endopeptidase-like (PREPL) gene. Previous reports have described patients with deletions and nonsense variants in PREPL, but nothing is known about the effect of missense variants in the pathology of CMS22. In this study, we have functionally characterized missense variants in PREPL from 3 patients with CMS22, all with hallmark phenotypes. Biochemical evaluation revealed that these missense variants do not impair hydrolase activity, thereby challenging the conventional diagnostic criteria and disease mechanism. Structural analysis showed that the variants affect regions most likely involved in intraprotein or protein-protein interactions. Indeed, binding to a selected group of known interactors was differentially reduced for the 3 variants. The importance of nonhydrolytic functions of PREPL was investigated in catalytically inactive PREPL p.Ser559Ala cell lines, which showed that hydrolytic activity of PREPL is needed for normal mitochondrial function but not for regulating AP1-mediated transport in the transgolgi network. In conclusion, these studies showed that CMS22 can be caused not only by deletion and truncation of PREPL but also by missense variants that do not necessarily result in a loss of hydrolytic activity of PREPL.

Authors

Yenthe Monnens, Anastasia Theodoropoulou, Karen Rosier, Kritika Bhalla, Alexia Mahy, Roeland Vanhoutte, Sandra Meulemans, Edoardo Cavani, Aleksandar Antanasijevic, Irma Lemmens, Jennifer A. Lee, Catherine J. Spellicy, Richard J. Schroer, Ricardo A. Maselli, Chamindra G. Laverty, Patrizia Agostinis, David J. Pagliarini, Steven Verhelst, Maria J. Marcaida, Anne Rochtus, Matteo Dal Peraro, John W.M. Creemers

×

Figure 2

Protein stability of CMS22 patient PREPL variants.

Options: View larger image (or click on image) Download as PowerPoint
Protein stability of CMS22 patient PREPL variants.
(A) Recombinant p.Arg...
(A) Recombinant p.Arg243Cys, p.Arg647Gln mutants and the catalytically inactive p.Ser559Ala PREPL variant are soluble and monomeric by size exclusion chromatography. Recombinant p.Ile412Arg PREPL mutant aggregates in vitro, eluting in the void volume (8 mL). (B) CD spectra of CMS22 mutants, which share the same secondary structure as the WT protein. (C) Normalized thermal denaturation curves monitored by measuring the CD signal at 217 nm across a temperature range from 4°C to 95°C. The melting temperature (Tm) of PREPL WT and the p.Ser559Ala and p.Arg647Gln mutants is calculated to be 63.5°C, while the melting temperature of p.Arg243Cys is 61.5°C. The unfolding process of all PREPL variants displays a 2-step pattern, with the first unfolding step occurring at approximately 50°C. (D) Structure of PREPL p.Arg243Cys mutant solved by cryo-EM in the open conformation, sharing the same fold as the WT protein. (E) Protein halflife measured by pulse chase. Representative blot of PREPL abundance after 0, 5, 10, and 15 hours of chase and quantified halflife time for WT and variant PREPL. (n = 3) Statistical analysis was performed using 1-way ANOVA.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts